947 - Augmentation of the cytotoxicity of ibandronate by y-27632 in prostate cancer cell lines

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Cancer Biology
Prostate Cancer
Basic Scientific Principles
Presenter Alper Ata
Authors A. Ata1, A. Özçimen2, H. Kurt3, N. Tiftik4, A. Arican5, K. Büyükafşar4
  • 1Mersin State Hospital, 33050 - Mersin/TR
  • 2Biology, Mersin University Science and Art Faculty, Mersin/TR
  • 3Dept Of Pharmacology, 3Mersin University School Of Medicine, Mersin/TR
  • 4Dept Of Pharmacology, Mersin University School Of Medicine, Mersin/TR
  • 5Dept. Of Medical Oncology, Mersin University School Of Medicine, Mersin/TR



Bisphosphonates, which have been used for the treatment of the metastatic bone disease and malignant hypercalcemia due many cancers. These drugs also inhibit mevalonate pathway that results in the reduction of Ras prenylation, which eventually inhibits tumor growth. Rho/Rho kinase signaling has a fundamental role in cancer cell proliferation, migration and metastasis. In this study, we aimed to investigate the effects of y-27632 (a Rho-kinase inhibitor) and ibandronate (a bisphosphonate) and their combination on cell proliferation in prostate cell lines.


The adherent prostate cell line, PC-3, was grown in RPMI-1640 supplemented with 10% fetal bovine serum, 1% L-glutamine, 1% penicillin (10.000U/ml) and streptomycin (10.000 mg/ml) in a humidified atmosphere of 5% CO2 at 37 oC for confluency. The cells were seeded in the wells of E-plates (24,000 cells/well) that allowed a real-time-monitoring of the cell index reflected cell growth and proliferation (xCELLigence, Roche). The cell index was evaluated at the different points of time (post-treatment 12, 24, 36, 48, 60 and 72 h) in the groups of, y-27632, ibandronate, the combination of these drugs and time-course control.


Both ibandronate alone (10-100 mM) and y-27632 alone (50-100 mM) markedly decreased cell index. But the combination of ibandronate with y-27632 (in differrent concentrations but especially in higher concentrations) resulted in potentiation of cytotoxicity in prostate cell line.


Rho kinase inhibitors, bisphosphonates and their combinations may be used for the treatment of prostate cancer in the future, according to the possible beneficial results of clinical trials.


All authors have declared no conflicts of interest.